Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement

被引:2
作者
María L Cuestas [1 ]
José R Oubia [1 ]
Verónica L Mathet [1 ]
机构
[1] Institutode Investigaciones en Microbiología y Parasitología Médica(IMPaM,UBA-CONICET),Facultad de Medicina, Universidad de Buenos Aires-Consejo Nacional de Investigaciones Científicas y Técnicas,Paraguay 2155,Buenos Aires,Argentina
关键词
Hepatocellular carcinoma; Therapy; Multidrug resistance; Drug delivery systems; Liver targeting;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma(HCC) is the most frequent form of liver cancer and the third most common cause of cancer-related death in the world. The main risk factor worldwide for this type of malignancy is chronic hepatitis caused by hepatitis B virus and hepatitis C virus infections. Advances in early detection and treatmenthave improved life expectancy of patients with HCC. However, this disorder remains as a disease with poor prognosis. In fact, epidemiological studies have revealed that there is an 8-mo median survival rate in patients, approximately 20% of whom survive one year while only 5% remain alive after three years. Additionally, HCC is particularly difficult to treat because of its high recurrence rate, and its resistance to conventional chemotherapy is due, among other mechanisms, to several members of the ATP-Binding Cassette protein family involved in drug transport being overexpressed. Fortunately, there is evidence that these patients may benefit from alternative molecular-targeted therapies. This manuscript intends to provide further insight into the etiology and molecular mechanisms related to HCC development and the latest therapeutic approaches to treat this malignancy. The development of effective delivery systems of antitumor drugs able to target the liver parenchyma is also assessed. Finally, the prospects in the development of more efficient drug therapies to overcome multidrug resistance are also examined.
引用
收藏
页码:96 / 116
页数:21
相关论文
共 69 条
[1]  
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence[J]. Chun-Jen Liu,Juliana Chang,Po-Huang Lee,Deng-Yn Lin,Cheng-Chung Wu,Long-Bin Jeng,Yih-Jyh Lin,King-Tong Mok,Wei-Chen Lee,Hong-Zen Yeh,Ming-Chih Ho,Sheng-Shun Yang,Mei-Due Yang,Ming-Chin Yu,Rey-Heng Hu,Cheng-Yuan Peng,Kuan-Lang Lai,Stanley Shi-Chung Chang,Pei-Jer Chen.World Journal of Gastroenterology. 2014(32)
[2]   Current approach in the treatment of hepatocellular ca [J].
Luigi Rossi ;
Federica Zoratto ;
Anselmo Papa ;
Francesca Iodice ;
Marina Minozzi ;
Luigi Frati ;
Silverio Tomao .
World Journal of Gastrointestinal Oncology, 2010, 2 (09) :348-359
[3]   应用双色FISH技术检测肝癌中HER-2的定量扩增及其临床意义 [J].
黄必军 ;
黄铁军 ;
梁启万 ;
黄楚文 ;
方嬿 .
遗传学报, 2001, (09) :793-800+894
[4]  
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial[J] . Masatoshi Kudo,Guohong Han,Richard S. Finn,Ronnie T.P. Poon,Jean‐Frederic Blanc,Lunan Yan,Jijin Yang,Ligong Lu,Won‐Young Tak,Xiaoping Yu,Joon‐Hyeok Lee,Shi‐Ming Lin,Changping Wu,Tawesak Tanwandee,Guoliang Shao,Ian B. Walters,Christine Dela Cruz,Valerie Poulart,Jian‐Hua Wang.Hepatology . 2014 (5)
[5]  
Hepatocellular carcinoma: systemic therapies and future perspectives[J] . Mikhail,Cosgrove,Zeidan.Expert Review of Anticancer Therapy . 2014 (10)
[6]  
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis[J] . Lucile Astorgues-Xerri,Maria E. Riveiro,Annemila? Tijeras-Raballand,Maria Serova,Gabriel A. Rabinovich,Ivan Bieche,Michel Vidaud,Armand de Gramont,Mathieu Martinet,Esteban Cvitkovic,Sandrine Faivre,Eric Raymond.European Journal of Cancer . 2014 (14)
[7]   Novel self-assembled micelles based on palmitoyl-trimethyl-chitosan for efficient delivery of harmine to liver cancer [J].
Bei, Yong-Yan ;
Yuan, Zhi-Qiang ;
Zhang, Liang ;
Zhou, Xiao-Feng ;
Chen, Wei-Liang ;
Xia, Peng ;
Liu, Yang ;
You, Ben-Gang ;
Hu, Xiao-Juan ;
Zhu, Qiao-Ling ;
Zhang, Chun-Ge ;
Zhang, Xue-Nong ;
Jin, Yong .
EXPERT OPINION ON DRUG DELIVERY, 2014, 11 (06) :843-854
[8]   Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy [J].
Zarva, Alina ;
Mohnike, Konrad ;
Damm, Robert ;
Ruf, Juri ;
Seidensticker, Ricarda ;
Ulrich, Gerhard ;
Seidensticker, Max ;
Pech, Maciej ;
Ricke, Jens ;
Amthauer, Holger .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (03) :360-366
[9]  
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells[J] . Dali Zhao,Bo Zhai,Changjun He,Gang Tan,Xian Jiang,Shangha Pan,Xuesong Dong,Zheng Wei,Lixin Ma,Haiquan Qiao,Hongchi Jiang,Xueying Sun.Cellular Signalling . 2014
[10]  
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study[J] . Armando Santoro,Lorenza Rimassa,Ivan Borbath,Bruno Daniele,Stefania Salvagni,Jean Luc Van Laethem,Hans Van Vlierberghe,J?rg Trojan,Frank T Kolligs,Alan Weiss,Steven Miles,Antonio Gasbarrini,Monica Lencioni,Luca Cicalese,Morris Sherman,Cesare Gridelli,Peter Buggisch,Guido Gerken,Roland M Schmid,Corrado Boni,Nicola Personeni,Ziad Hassoun,Giovanni Abbadessa,Brian Schwartz,R